Ying Wang

Ying Wang

Auto-generated profile, based on publicly available information

Ying Wang

Department of Medical Ultrasonics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2022 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
LWLei Wu
Lei Wu
WYWeitao Ye
Weitao Ye
YLYu Liu
Yu Liu
DCDong Chen
Dong Chen
YWYuxiang Wang
Yuxiang Wang
YWYing Wang
Ying Wang
Background: The biological phenotype of tumours evolves during neoadjuvant chemotherapy (NAC). Accurate prediction of pathological complete response (pCR) to NAC in the early-stage or posttreatment can optimize treatment strategies or improve the breast-conserving rate. This study aimed to develop and validate an autosegmentation-based serial ultrasonography assessment system (SUAS) that incorporated serial ultrasonographic features throughout the NAC of breast cancer to predict pCR. Methods: A total of 801 patients with biopsy-proven breast cancer were retrospectively enrolled from three institutions and were split into a training cohort (242 patients), an internal validation cohort (197 patients), and two external test cohorts (212 and 150 patients). Three imaging signatures were constructed from the serial ultrasonographic features before (pretreatment signature), during the first–second cycle of (early-stage treatment signature), and after (posttreatment signature) NAC based on autosegmentation by U-net. The SUAS was constructed by subsequently integrating the pre, early-stage, and posttreatment signatures, and the incremental performance was analysed. Results: The SUAS yielded a favourable performance in predicting pCR, with areas under the receiver operating characteristic curve (AUCs) of 0.927 [95% confidence interval (CI) 0.891–0.963] and 0.914 (95% CI 0.853–0.976), compared with those of the clinicopathological prediction model [0.734 (95% CI 0.665–0.804) and 0.610 (95% CI 0.504–0.716)], and radiologist interpretation [0.632 (95% CI 0.570–0.693) and 0.724 (95% CI 0.644–0.804)] in the external test cohorts. Furthermore, similar results were also observed in the early-stage treatment of NAC [AUC 0.874 (0.793–0.955)–0.897 (0.851–0.943) in the external test cohorts]. Conclusions: We demonstrate that autosegmentation-based SAUS integrating serial ultrasonographic features throughout NAC can predict pCR with favourable performance, which can facilitate individualized treatment strategies.

5 February 2022 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
CLChao-Qun Li
Chao-Qun Li
HHHui Huang
Hui Huang
SRSi-Min Ruan
Si-Min Ruan
HHHang-Tong Hu
Hang-Tong Hu
MXMeng-Fei Xian
Meng-Fei Xian
LCLi-Da Chen
Li-Da Chen

19 December 2012 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
FNFang Nie
Fang Nie
XLXin-Jie Li
Xin-Jie Li
PSPan-Feng Shang
Pan-Feng Shang
YWYing Wang
Ying Wang

2 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYanting Liang
Yanting Liang
ZWZhitao Wei
Zhitao Wei
YDYi Dai
Yi Dai
XCXiaobo Chen
Xiaobo Chen
SDSiyao Du
Siyao Du
ZSZhenwei Shi
Zhenwei Shi
Breast cancer diagnosis using magnetic resonance imaging remains limited by high false-positive rates and substantial inter-reader variability, especially for lesions classified as Breast Imaging Reporting and Data System (BI-RADS) category 4, often leading to unnecessary biopsies. Here we show that the BI-RADS 4 Lesions Analysis System (BL4AS), an artificial intelligence system powered by foundation models and leveraging the rich spatiotemporal information of dynamic contrast-enhanced MRI, addresses these diagnostic challenges. Developed on a multicenter dataset of 2,803 lesions from 2,686 female patients, BL4AS demonstrates robust performance with areas under the curve of 0.892-0.930 and significantly outperforms radiologists in specificity (0.889 versus 0.491). BL4AS-assisted interpretation significantly improves diagnostic accuracy for both senior and junior radiologists, reducing inter-reader variability by 24.5% and decreasing false-positive rates by 27.3%. BL4AS further stratifies lesions into subcategories (4 A, 4B and 4 C) for refined risk assessment, offering a practical tool for precision breast cancer management.

26 September 2025 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
CWChinting Wong
Chinting Wong
QYQi Yang
Qi Yang
YLYanting Liang
Yanting Liang
ZWZhitao Wei
Zhitao Wei
YDYi Dai
Yi Dai
ZSZhenwei Shi
Zhenwei Shi
Accurate classification of Human epidermal growth factor receptor 2 (HER2) expression is crucial for guiding treatment in breast cancer, especially with emerging therapies like trastuzumab deruxtecan (T-DXd) for HER2-low patients. Current gold-standard methods relying on invasive biopsy and immunohistochemistry suffer from sampling bias and interobserver variability, highlighting the need for reliable non-invasive alternatives. We developed an artificial intelligence framework that integrates a pretrained foundation model with a task-specific classifier to predict HER2 expression categories (HER2-zero, HER2-low, HER2-positive) directly from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). The model was trained and validated using multicenter datasets. Model interpretability was assessed through feature visualization using t-SNE and UMAP dimensionality reduction techniques, complemented by SHAP analysis for post-hoc interpretation of critical predictive imaging features. The developed model demonstrated robust performance across datasets, achieving micro-average AUCs of 0.821 (95% CI 0.795–0.846) and 0.835 (95% CI 0.797–0.864), and macro-average AUCs of 0.833 (95% CI 0.818–0.847) and 0.857 (95% CI 0.837–0.872) in external validation. Subgroup analysis demonstrated strong discriminative power in distinguishing HER2 categories, particularly HER2-zero and HER2-low cases. Visualization techniques revealed distinct, biologically plausible clustering patterns corresponding to HER2 expression categories. This study presents a reproducible, non-invasive solution for comprehensive HER2 phenotyping using DCE-MRI, addressing fundamental limitations of biopsy-dependent assessment. Our approach enables accurate identification of HER2-low patients who may benefit from novel therapies like T-DXd. This framework represents a significant advancement in precision oncology, with potential to transform diagnostic workflows and guide targeted therapy selection in breast cancer care.

13 December 2022 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
YLYu Liu
Yu Liu
YWYing Wang
Ying Wang
SFSenwen Feng
Senwen Feng
ZXZeyan Xu
Zeyan Xu
MYMengxia Yao
Mengxia Yao
ZLZaiyi Liu
Zaiyi Liu